These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 16061029

  • 1. [Mechanism of inhibiting the proliferation of prostate cancer by finasteride: a study using cDNA microarray].
    Chen G, Geng J, Zhang YF.
    Zhonghua Yi Xue Za Zhi; 2005 Jun 08; 85(21):1489-92. PubMed ID: 16061029
    [Abstract] [Full Text] [Related]

  • 2. Change of the cell cycle after flutamide treatment in prostate cancer cells and its molecular mechanism.
    Wang Y, Shao C, Shi CH, Zhang L, Yue HH, Wang PF, Yang B, Zhang YT, Liu F, Qin WJ, Wang H, Shao GX.
    Asian J Androl; 2005 Dec 08; 7(4):375-80. PubMed ID: 16281084
    [Abstract] [Full Text] [Related]

  • 3. Androgen receptor-dependent PSA expression in androgen-independent prostate cancer cells does not involve androgen receptor occupancy of the PSA locus.
    Jia L, Coetzee GA.
    Cancer Res; 2005 Sep 01; 65(17):8003-8. PubMed ID: 16140973
    [Abstract] [Full Text] [Related]

  • 4. Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo.
    Chen Q, Watson JT, Marengo SR, Decker KS, Coleman I, Nelson PS, Sikes RA.
    Cancer Lett; 2006 Dec 08; 244(2):274-88. PubMed ID: 16500022
    [Abstract] [Full Text] [Related]

  • 5. Evolution of the androgen receptor pathway during progression of prostate cancer.
    Hendriksen PJ, Dits NF, Kokame K, Veldhoven A, van Weerden WM, Bangma CH, Trapman J, Jenster G.
    Cancer Res; 2006 May 15; 66(10):5012-20. PubMed ID: 16707422
    [Abstract] [Full Text] [Related]

  • 6. Molecular regulation of androgen action in prostate cancer.
    Dehm SM, Tindall DJ.
    J Cell Biochem; 2006 Oct 01; 99(2):333-44. PubMed ID: 16518832
    [Abstract] [Full Text] [Related]

  • 7. Expression profiling of androgen-dependent and -independent LNCaP cells: EGF versus androgen signalling.
    Oosterhoff JK, Grootegoed JA, Blok LJ.
    Endocr Relat Cancer; 2005 Mar 01; 12(1):135-48. PubMed ID: 15788645
    [Abstract] [Full Text] [Related]

  • 8. Differential expression of steroid 5alpha-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer.
    Das K, Lorena PD, Ng LK, Lim D, Shen L, Siow WY, Teh M, Reichardt JK, Salto-Tellez M.
    Endocr Relat Cancer; 2010 Sep 01; 17(3):757-70. PubMed ID: 20519274
    [Abstract] [Full Text] [Related]

  • 9. Zanthoxyli Fructus induces growth arrest and apoptosis of LNCaP human prostate cancer cells in vitro and in vivo in association with blockade of the AKT and AR signal pathways.
    Yang Y, Ikezoe T, Takeuchi T, Adachi Y, Ohtsuki Y, Koeffler HP, Taguchi H.
    Oncol Rep; 2006 Jun 01; 15(6):1581-90. PubMed ID: 16685399
    [Abstract] [Full Text] [Related]

  • 10. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles.
    Tamura K, Furihata M, Tsunoda T, Ashida S, Takata R, Obara W, Yoshioka H, Daigo Y, Nasu Y, Kumon H, Konaka H, Namiki M, Tozawa K, Kohri K, Tanji N, Yokoyama M, Shimazui T, Akaza H, Mizutani Y, Miki T, Fujioka T, Shuin T, Nakamura Y, Nakagawa H.
    Cancer Res; 2007 Jun 01; 67(11):5117-25. PubMed ID: 17545589
    [Abstract] [Full Text] [Related]

  • 11. Prostate specific antigen gene expression in androgen insensitive prostate carcinoma subculture cell line.
    Tsui KH, Feng TH, Chung LC, Chao CH, Chang PL, Juang HH.
    Anticancer Res; 2008 Jun 01; 28(4A):1969-76. PubMed ID: 18649734
    [Abstract] [Full Text] [Related]

  • 12. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
    Tepper CG, Vinall RL, Wee CB, Xue L, Shi XB, Burich R, Mack PC, de Vere White RW.
    Prostate; 2007 Apr 01; 67(5):521-35. PubMed ID: 17252539
    [Abstract] [Full Text] [Related]

  • 13. Valproic acid induces neuroendocrine differentiation and UGT2B7 up-regulation in human prostate carcinoma cell line.
    Valentini A, Biancolella M, Amati F, Gravina P, Miano R, Chillemi G, Farcomeni A, Bueno S, Vespasiani G, Desideri A, Federici G, Novelli G, Bernardini S.
    Drug Metab Dispos; 2007 Jun 01; 35(6):968-72. PubMed ID: 17371798
    [Abstract] [Full Text] [Related]

  • 14. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
    Lee SO, Yeon Chun J, Nadiminty N, Trump DL, Ip C, Dong Y, Gao AC.
    Prostate; 2006 Jul 01; 66(10):1070-5. PubMed ID: 16637076
    [Abstract] [Full Text] [Related]

  • 15. Sodium butyrate regulates androgen receptor expression and cell cycle arrest in human prostate cancer cells.
    Kim J, Park H, Im JY, Choi WS, Kim HS.
    Anticancer Res; 2007 Jul 01; 27(5A):3285-92. PubMed ID: 17970072
    [Abstract] [Full Text] [Related]

  • 16. Molecular signatures of soy-derived phytochemicals in androgen-responsive prostate cancer cells: a comparison study using DNA microarray.
    Takahashi Y, Lavigne JA, Hursting SD, Chandramouli GV, Perkins SN, Kim YS, Wang TT.
    Mol Carcinog; 2006 Dec 01; 45(12):943-56. PubMed ID: 16865672
    [Abstract] [Full Text] [Related]

  • 17. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
    Koochekpour S, Lee TJ, Wang R, Culig Z, Delorme N, Caffey S, Marrero L, Aguirre J.
    Prostate; 2007 Feb 01; 67(2):178-89. PubMed ID: 17044040
    [Abstract] [Full Text] [Related]

  • 18. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
    Zhu ML, Partin JV, Bruckheimer EM, Strup SE, Kyprianou N.
    Prostate; 2008 Feb 15; 68(3):287-95. PubMed ID: 18163430
    [Abstract] [Full Text] [Related]

  • 19. Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy.
    Haram KM, Peltier HJ, Lu B, Bhasin M, Otu HH, Choy B, Regan M, Libermann TA, Latham GJ, Sanda MG, Arredouani MS.
    Prostate; 2008 Oct 01; 68(14):1517-30. PubMed ID: 18668517
    [Abstract] [Full Text] [Related]

  • 20. Androgen receptor action in hormone-dependent and recurrent prostate cancer.
    Agoulnik IU, Weigel NL.
    J Cell Biochem; 2006 Oct 01; 99(2):362-72. PubMed ID: 16619264
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.